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Simple Summary: Cancer deaths are predominantly due to metastases rather than the primary
tumors, and thus there is an urgent need for the discovery of more effective drug therapies for
metastatic cancer. Recent genomics, transcriptomics, and proteomics studies have identified tyrosine
kinase 2 (TYK2) as an oncogene that is frequently mutated or overexpressed in many types of cancer
and metastases. A member of the Janus kinase (JAK) family, TYK2 mediates the signals of numerous
cytokines involved in immune and inflammatory signaling. In cancer cells, activation of TYK2 can
lead to decreased cell death as well as increased cell growth and invasion. Multiple drugs that
specifically block TYK2 or JAKs are currently FDA-approved or in clinical trials. In this review, we
provide an overview of the screening, molecular, and animal studies that have characterized the role
of TYK2 in cancer and metastases, and the potential of TYK2 inhibitors as effective cancer therapies.
Abstract: Advances in genomic analysis and proteomic tools have rapidly expanded identification
of biomarkers and molecular targets important to cancer development and metastasis. On an
individual basis, personalized medicine approaches allow better characterization of tumors and
patient prognosis, leading to more targeted treatments by detection of specific gene mutations,
overexpression, or activity. Genomic and proteomic screens by our lab and others have revealed
tyrosine kinase 2 (TYK2) as an oncogene promoting progression and metastases of many types
of carcinomas, sarcomas, and hematologic cancers. TYK2 is a Janus kinase (JAK) that acts as an
intermediary between cytokine receptors and STAT transcription factors. TYK2 signals to stimulate
proliferation and metastasis while inhibiting apoptosis of cancer cells. This review focuses on the
growing evidence from genomic and proteomic screens, as well as molecular studies that link TYK2
to cancer prevalence, prognosis, and metastasis. In addition, pharmacological inhibition of TYK2 is
currently used clinically for autoimmune diseases, and now provides promising treatment modalities
as effective therapeutic agents against multiple types of cancer.
Keywords: tyrosine kinase-2; TYK2; cancer; metastasis; genomics; proteomics; transcriptomics;
JAK; STAT
1. Genomics, Transcriptomics and Proteomics in Target Discovery: TYK2 in Cancer
Revolutionary advancements in bioinformatics techniques and computational data
analysis within the last decade have transformed modern cancer diagnostics and thera-
peutics [1]. Innovations in next-generation sequencing (NGS) have allowed large-scale
genomic and transcriptomic characterization, leading to the detection of novel genetic
alterations in numerous types of cancer [1,2]. High throughput proteomics utilizing protein
microarrays and mass spectrophotometry have similarly led to the discovery of proteins
with aberrant expression or kinase activity in cancer development and progression [3].
Genomic, transcriptomic and proteomic assays have led to identification of tyrosine
kinase 2 (TYK2) mutations, fusion proteins and expression changes in a variety of hema-
tological cancers, carcinomas and soft-tissue sarcomas [4]. TYK2 is an approximately 134
kDa protein identified in 1990 as the first member of the Janus kinase (JAK) family, which
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includes non-receptor tyrosine kinases that mediate cytokine signaling [5,6]. In humans,
the TYK2 gene is found on chromosome 19, and is ubiquitously expressed at varying levels
throughout the body [7]. Originally known for its immune modulatory role, TYK2 is now
emerging as an oncogene that could serve as both a prognostic biomarker and a promising
drug target in cancer [8]. In this review, we discuss the history of TYK2 with an emphasis
on the genomic, proteomic, and transcriptomic screens that have led to characterization of
the role of TYK2 in cancer and metastases.
1.1. TYK2 in Carcinomas and Sarcomas
While activating mutations in other members of the JAK family have long been known
to be tumorigenic, it has only been in the last 10 years that a series of screening studies
have shown the involvement of TYK2 as an oncogene driving cancer development and
metastases [9]. Early proteomic analyses first reported the role of TYK2 as a biomarker in
breast, cervical, colorectal and prostate cancers (Table 1) [10–13]. A dissociable antibody
microarray (DAMA) staining screen of hundreds of proteins, a technique that combines
immunostaining and protein microarrays, found that TYK2 protein levels were elevated
in breast cancer compared to normal breast cell-lines [10]. Likewise, proteomics using
two-dimensional (2D) gel electrophoresis followed by mass spectrometry showed increased
TYK2 protein expression in squamous cervical cancer tissue [11]. Similarly, in colorectal
cancer cells, high resolution mass spectrophotometry identified TYK2 as a phosphorylation
target of hepatocyte growth factor (HGF), which stimulates proliferation in these cells [12].
Proteomic phosphotyrosine peptide enrichment and quantitative mass spectrometry iden-
tified several activated kinases, including TYK2 (Y292) and its downstream target signal
transducer and activator of transcription 3 (STAT3) (Y705), in metastatic castration-resistant
prostate cancer [13]. In addition, RNA sequencing (RNA-seq) of the transcriptome revealed
that TYK2 and JAK3 mRNA levels were significantly increased in stomach adenocarcinoma,
and both proteins were found to be prognostic biomarkers [14].
Table 1. Genomic, transcriptomic and proteomic studies identify TYK2 mutations and expression in cancer.
Study Type Type of Screen forDiscovery
SNP, Variant,
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RA, SLE, IBD Protective [35]
Arrows (↑ or ↓) indicate increase or decrease, respectively, in proliferation, apoptosis or disease risk. Ref. = References, DAMA = dissociable
antibody microarray staining screen, nd = not determined, p-TYK2 = phosphorylated TYK2, HGF = hepatocyte growth factor, RNA-Seq
= RNA-Sequencing, NGS = next generation sequencing, GOF = gain of function, LOF = Loss of function, ALL = Acute lymphoblastic
leukemia, T-ALL = T-cell ALL, AML = Acute myeloid leukemia, ACLC = Anaplastic large cell lymphoma, Ph-like ALL = Philadelphia
chromosome-like ALL, RNAi = RNA interference, NPMI = nucleophosmin, NFKB2 = nuclear factor of kappa light polypeptide gene
enhancer in B cells 2, PABPC4 = poly(A) binding protein cytoplasmatic 4, MYB-TYK2 = v-myb avian myeloblastosis viral oncogene
homolog, GWAS = genome-wide association study, MS = multiple sclerosis (MS), IBD = inflammatory bowel disease, AS = ankylosing
spondylitis, RA = rheumatoid arthritis, SLE = systematic lupus erythematosus, T1D = Type-I diabetes, SSc = systemic sclerosis, eQTL =
expression quantitative trait locus.
Genomic screens have also implicated TYK2 as a pro-survival gene in soft-tissue
sarcomas (Table 1). Our laboratory utilized NGS and identified activating TYK2 mutations
in malignant peripheral nerve sheath tumors (MPNST), an aggressive subtype of sarcomas
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associated with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome [36].
Subsequent genetic knockdown of TYK2 in MPNST cell lines resulted in decreased tumor
growth and increased cell death [20]. Additionally, genetic knockdown of Tyk2 in murine
MPNST cells resulted in decreased tumor burden in subcutaneous tumors and metastatic
tumor models [20]. In line with these studies, genomic NGS profiling of over 100 patients
with multiple types of advanced recurrent, metastatic or refractory sarcomas found that
they harbored mutations in TYK2, JAK1, JAK2, and JAK3 [21].
1.2. TYK2 in Hematological Cancers
Hematological cancers, malignancies of the blood that arise from immune cells or
the bone marrow, include leukemia, lymphoma, and multiple myeloma. JAK2, and to a
lesser extent JAK1 and JAK3, play a major oncogenic role in multiple types of leukemia,
often undergoing gain-of-function (GOF) mutations and translocations [37,38]. TYK2
GOF point mutations occur less frequently in leukemia, although many single nucleotide
polymorphisms (SNPs) in the coding region of the TYK2 gene have been described, with
over 100 nonsynonymous mutations associated with a number of diseases (Table 1) [39].
Acute lymphoblastic leukemia (ALL) is a subset of leukemia associated with chromosomal
rearrangements or genetic mutations that encode for transcription factors that drive cancer
progression [40]. At the transcriptome level, an RNA interference (RNAi) screen engaging
short hairpin RNA (shRNA) against over 1700 genes in T-cell acute lymphoblastic leukemia
(T-ALL) cell lines found that TYK2 promotes cell growth and survival downstream of
IL-10, through STAT1 and BCL2 signaling, while TYK2 inhibitors decreased cell prolifera-
tion [18]. Sequencing revealed gain-of-function (GOF) TYK2 point mutations in the FERM,
JH2, and kinase domains [18]. In pediatric ALL patients, whole exome sequencing identi-
fied TYK2 mutations in the JH2 pseudokinase domain (G761V and P760L) that promote
TYK2 autophosphorylation, activate STAT1/3/5, and are suggested to contribute to the
development of leukemia [23,24]. Another subtype, Philadelphia chromosome (Ph)-like
ALL, contains multiple kinase-activating alterations in two-thirds of patients, including
activation of TYK2, as determined by a NGS genomic profiling of 1725 patients [25,26].
Furthermore, high-throughput sequencing of the kinase domains of tyrosine kinase genes
identified a SNP, rs2304255 (TYK2-G363S), in the TYK2 kinase domain that was associated
with acute myeloid leukemia (AML), although it is unclear as to the impact of this mutation
on TYK2 function [27].
Additionally, four TYK2 fusion proteins have been identified in several hematologic
cancers using genomic and transcriptomic sequencing [17,19,25]. In a T-cell lymphoma
cell-line, whole-transcriptome screening found a TYK2 fusion protein with nucleophosmin
(NPMI), NPMI-TYK2, which includes the kinase domain and a partial pseudokinase
domain of TYK2 [19]. The NPMI-TYK2 fusion protein contains a constitutively active
TYK2, leading to constitutively phosphorylated STAT1, 3 and 5 [19]. Numerous genomic
rearrangements were discovered in human anaplastic large cell lymphoma (ACLC) patients
with an RNAseq screen, including two fusions of TYK2 to nuclear factor of kappa light
polypeptide gene enhancer in B cells 2 (NFκB2) or poly(A) binding protein cytoplasmic 4
(PABPC4) [17]. Cells with the NFκB2-TYK2 fusion protein exhibited constitutively active
TYK2, JAK2, and STAT3, resulting in greater colony forming capacity [17]. Correspondingly,
TYK2 is highly expressed in lymphomas including ALCL, and activated TYK2 leads to
increased ALCL cell survival, which is mediated through STAT1/3 and the anti-apoptotic
protein MCL-1 [41]. In the Ph-like ALL genomic screen, the v-myb avian myeloblastosis
viral oncogene homolog (MYB) was merged with TYK2 to form MYB-TYK2 [25]. While
this fusion protein includes the TYK2 kinase domain and part of the pseudokinase domain,
the study did not assess activation of TYK2 and downstream STATs [25].
1.3. Other Actions of TYK2 in Cancer
Similar to what is seen with other genes, the role of TYK2 in malignancy is complex
and likely is cell type and context dependent. In some settings, TYK2 appears to play a
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role in suppressing tumor growth, and a few studies have reported lower TYK2 expres-
sion or loss-of-function (LOF) mutations associated with cancer development or progres-
sion [15,28,42,43]. In a proteomics screen for tyrosine kinase variants, multiple brain and
hematopoietic cancer cell lines harbored an inactivating TYK2 splice variant, E971fsX67 [15].
Mice with knockout of Tyk2 were more susceptible to xenograft tumor growth and metasta-
sis of breast cancer 4T1 cells, and Tyk-/- mice also developed leukemia and lymphoma at
an increased rate, both likely due to defective tumor immunosurveillance [42,43]. Tumor
immunosurveillance is the process of the host immune system identifying and destroying
malignant or pre-cancerous cells [44]. Amplicon-based NGS revealed TYK2 variants with
catalytic LOF in 25% of B-cell ALL (B-ALL) patients, as well as lower TYK2 gene expression
overall in B-ALL [28]. These LOF TYK2 variants failed to phosphorylate STAT3 in cells
in vitro, and further support the immunosurveillance role of TYK2 in cancer [28]. However,
the intracellular mechanisms by which TYK2 deficiency within cancer cells may promote
tumorigenesis in a cell autonomous manner under certain circumstances remains unclear.
A computational analysis found that the TYK2 rs34536443 variant (P1104A) conferred
increased cancer risk, and this mutation was subsequently detected in several cancers,
including MPNST, breast cancer, colon cancer, stomach cancer and AML [27,36,45]. Located
within the activation loop of the highly conserved kinase domain, the P1104A mutation
is predicted to cause activation of the catalytic domain [36,45]. Functional studies found
that immune cells with the TYK2 P1104A variant exhibited impaired auto-phosphorylation
in response to ATP or IFN-α [39]. Nevertheless, TYK2 P1104A transduced signaling of
IFN-α/β, IL-6 and IL-10 to phosphorylate downstream STATs, suggesting that pairing
with a catalytically competent JAK is sufficient for cytokine signaling [39]. In addition,
the TYK2 P1104A variant corresponded to TYK2 overexpression in MPNST tumors [20].
Thus, the TYK2 P1104A variant may drive carcinogenesis through relative changes in the
different TYK2-mediated cytokine signaling pathways and downstream STAT-induced
gene transcription.
2. TYK2 Signaling: Intermediary of Cytokine Signaling and STATs
The JAK family of non-receptor tyrosine kinases is composed of TYK2 and JAK1-3 [46].
TYK2 and JAK1-3 associate with the type I and type II cytokine receptor superfamily,
heterodimeric or multimeric receptors without intrinsic kinase activity [47]. TYK2 mediates
signal transduction for many cytokines, including interferons (IFN) and interleukins (IL),
through association with five receptor chains: IFN-α/β receptor 1 (IFNAR1), IL-12 receptor-
β1 (IL-12Rβ1), IL-10 receptor β (IL-10Rβ), IL-13 receptor α (IL-13Rα) and gp130 [48]. When
an extracellular ligand binds to and activates its receptor, conformational changes in the
transmembrane receptors bring JAKs close together, where they are activated by auto- or
trans-phosphorylation and subsequently phosphorylate intracellular tyrosine residues on
the receptors [49]. TYK2 heterodimerizes with JAK1 or JAK2, but not JAK3, depending on
the cytokine and receptor complex [50]. Activated JAKs then recruit and phosphorylate
signal transducers and activators of transcription (STAT), which has seven family members
(STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6) [51]. TYK2 specifically
transduces activation of STAT1, STAT3 and STAT5A/B. Phosphorylated STATs then homo-
or hetero-dimerize, allowing translocation to the nucleus where STAT dimers bind on the
promoters of target genes to induce transcription.
2.1. TYK2 Structure and Post-Translational Modifications
In vertebrates, JAK1-3 and TYK2 are highly conserved proteins with seven homology
domains (JH1-JH7). These form four structural domains: (1) the four-point-one, ezrin,
radixin, moesin (FERM) homology domain (part of JH4 and JH5-JH7), (2) src-homology 2
(SH2) domain (JH3 and part of JH4), (3) pseudokinase (kinase-like) domain (JH2), and (4)
kinase domain (JH1) (Figure 1) [47,52]. The N-terminal FERM domain facilitates interaction
of TYK2/JAK1-3 with the intracellular tails of receptors, while the adjacent SH2 domain
is responsible for binding to receptors [53,54]. Various mutations to the catalytically
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inactive pseudokinase domain can result in either increased or decreased kinase activity [4].
Thus, the JH2 pseudokinase domain functions as a negative regulator of kinase activity
in the absence of receptor activation, and conversely, to communicate the signal from the
ligand-activated receptor to the JH1 kinase domain [55]. The catalytically active kinase
domain on the C-terminal end of TYK2 contains two adjacent tyrosine residues (Y1054
and Y1055) in its activation loop that are auto-/trans-phosphorylated by ligand-binding
induced conformational changes in its receptors [47,56]. TYK2 also contains several other
phosphorylation sites located throughout all four domains, including tyrosine residues
(Y292, Y433, Y827, Y884, and Y1145) and serine residues (S491, S499) [53,57]. Further
post-translational modifications of TYK2 besides phosphorylation have not been widely
studied.
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In a negative feedback loop, STATs induce transcription of suppressor of cytokine
signaling (SOCS) genes [58]. SOCS1-7 proteins function as E3 ubiquitin ligases to target
JAKs for ubiquitination and degradation via the proteasome [59,60]. In addition, SOCS1
and SOCS3 can bind to the JH1 domain of JAKs to inhibi kinase activity [61]. TYK2
signaling is also inhibited through de-phosph rylation by protein tyrosine phosphatase 1B
(PTP1B), src homology 2 domain containing protein tyrosine phosphatase-1 (SHP1), and
CD45 [62–64]. Additionally, a protein chaperone, heat-shock protein 90 (HSP90), has been
shown to interact with and stabilize TYK2 and other JAKs in cancer cells, and thus is a
promising therapeutic target [36,65].
2.2. Interferons
The earliest studies on TYK2 signaling found it to be an intermediate in the IFNα and
IFNβ pathways (Figure 2) [66]. Subsequently, TYK2 was shown to primarily be involved
in the signaling of type I and type 2 IFNs [67,68]. The type I IFN family is a large group
of mainly IFNα subtypes and IFNβ, as well as IFNε, IFNκ, IFNω, and IFNζ, and these
cytokines are involved in anti-viral immunity a d anti-canc r immunity [69–72]. The
ubiquitously expressed type I IFNs bind to the IFNAR2 chain that is associated with JAK1,
which then recruits the IFNAR1 chain associated with TYK2 [73]. Activated TYK2/JAK1
then typically phosphorylates a STAT1 and STAT2 dimer, and to a lesser extent STAT1
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homodimers [74]. Other STATs (STAT3, STAT4, and STAT6) can also transduce type I IFN
signaling in some conditions and cell-types [70]. The STAT1/STAT2 dimer complexes
with the cofactor interferon regulatory factor 9 (IRF9) to bind to IFN-stimulated response
elements (ISRE), while the STAT1/STAT1 homodimer binds to interferon-γ activated
sequences (GAS) in promoter regions of IFN-targeted genes [72,73]. Type I IFNs stimulate
transcription of over 1000 genes implicated in regulation of inflammatory and immune
functions, including in cancer [72].
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TYK2 also associates with the IL-10R2 chain which, in combination with the JAK1-
associated IL-28R chain, mediates signal transduction of type III IFNs through STAT1/STAT2
heterodimers and IRF9 [75,76]. The type III IFN family includes IFNλ1 (IL-29), IFNλ2 (IL-
28A), IFNλ3 (IL-28B) and IFNλ4, which can also induce phosphorylation of the other
STATs [77,78]. IFNλs are thought to be responsible for initial host responses against minor
infections and epithelial layer damage [78]. Large-scale systemic infections subsequently
illicit the stronger type I IFN defense [70]. However, activation of type I IFNs can lead to a
systemic overactive immune response or inflammation [79].
2.3. Interleukins
The IL-12 family and the IL-10 family of cytokines also utilize TYK2 signal transduction
in a balance of immunomodulatory and inflammatory responses. Members of the IL-12
family (IL-12 and IL-23) bind to JAK-associated IL-12Rβ2 or IL-23R chains, respectively,
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which heterodimerizes with the TYK2-associated IL-12Rβ1 chain to activate primarily
STAT4 and STAT3, respectively (Figure 2) [50]. STAT1 and STAT5 can also be activated
depending on cell context [80]. IL-12 and IL-23 have counteracting functions in immune
function, inflammation and cancer development [81]. IL-12 is important in cell-mediated
immunity, while IL-23 promotes inflammation [82].
IL-10 family members are essential anti-inflammatory cytokines with immunosup-
pressive actions that promote epithelial homeostasis and barrier function in response to
infection or inflammatory conditions, while IL-10 deficiency is involved in autoimmune
disorders [76]. However, IL-10 has opposing immune stimulatory actions depending on
cell type and circumstance [83]. The IL-10 family of cytokines include IL-10, IL-22, IL-26
and IFNλs, which bind to their specific JAK1-associated receptor chains and to the TYK2-
associated IL-10R2 chain (IL-10Rβ), leading to phosphorylation of STAT3 homodimers,
with a minor component through STAT1 and STAT5 [47,84].
Other cytokines that signal through TYK2 include those that bind to the gp130 receptor
subunit, e.g., IL-6, IL-11, IL-27, oncostatin M (OSM), cardiotrophin-1 (CT-1), and leukemia
inhibitory factor (LIF). However, TYK2 is redundant with other JAKs in these pathways. A
full list of cytokines and receptors reported to signal through TYK2 have been reviewed
previously [44,47].
3. Immune Modulatory and Inflammatory Effects of TYK2
Immune surveillance against cancer cells and chronic inflammation both influence the
microenvironment surrounding tumors throughout their development and metastasis [85].
Inflammatory cytokine signaling can stimulate cancer cell proliferation, migration, and
invasion [86]. The family of JAK kinases transduce cytokine-derived signals needed for
a functional immune response [7]. Indeed, TYK2 was originally recognized for its roles
in immunity and inflammation, with TYK2 primarily mediating the effect of cytokine
signaling pathways vital for adaptive and innate immune responses [53]. Given the
establishment of TYK2 as a susceptibility gene in auto-inflammation, immunodeficiency
and other immune responses as well as in cancer [39,87,88], the prospect of therapies
targeting TYK2 in immunodeficiency and autoimmune diseases exists.
TYK2 deficiency, often via LOF mutations, is frequently involved in severe immun-
odeficiency. Clinical appearances of TYK2 deficiency are typically mycobacterial and/or
viral infections, caused by impaired responses to IL-12 and IFN-α/β [89]. STAT3 and TYK2
signaling alterations are associated with Hyper IgE syndrome (HIES), a rare immunodefi-
ciency characterized by elevated serum immunoglobulin E (IgE), skin inflammation, and
recurrent skin and lung infections [90,91]. Similarly, mutations in STAT3 are associated
with the autosomal dominant form of HIES, which also features skeletal, connective tissue
and pulmonary abnormalities [92]. The recessive form, characterized by viral infections
and neurologic complications, has been linked to TYK2 deficiency; however, the genetic
cause is still under investigation [91,93,94]. Several reports describe patients with non-
functional TYK2 that have exhibited features of HIES. One patient with complete TYK2
deficiency suffered from frequent bacterial and viral infections as well as HIES-like dis-
ease [95]. Two other patients with nonsense TYK2 mutations displayed characteristics of
HIES, but did not experience significant viral or bacterial infections [96,97]. However, seven
other TYK2-null patients exhibited viral or mycobacterial infections through diminished
IFN-α, IFN-β, and IL-12 signaling, without signs of HIES [89]. In mice, elimination of Tyk2
produces immunological dysfunctions making the mice highly susceptible to infections
and some tumors [68,98,99]. Thus, it is debated whether loss of TYK2 primarily results in
viral/mycobacterial infections and constitutes a separate disorder from HIES [89].
While TYK2 deficiency is accompanied by recurrent viral and bacterial infections,
elevated TYK2 activity is also connected with complications of viral infections. A large
GWAS analysis reported TYK2 as a genetic locus (rs74956615) associated with severity of
COVID-19 disease caused by the novel SARS-CoV-2 virus, with high TYK2 gene expression
found in critically ill COVID-19 patients [29]. Several JAK inhibitors, e.g., ruxolitinib
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(JAK1/2), baricitinib (JAK1/2), and tofacitinib (JAK1/2/3, TYK2), are currently in clinical
trials for COVID-19 [100]. The combination of baricitinib, a non-specific JAK inhibitor, with
the anti-viral remdesivir reduced mortality and improved recovery time in hospitalized
COVID-19 patients [101]. In lung cultures infected with Influenza A virus, TYK2 inhibition
improved the innate immune response through IL-1B, reducing the development of sec-
ondary bacterial pneumonia [102]. Thus, TYK2 is a potential target for treatment of patients
with COVID-19 or viral pneumonia to combat overactive cytokine inflammation [103].
Genetic association studies have also linked the TYK2 gene to the risk of developing
many autoimmune diseases [34]. Likewise, while Tyk2-/- mice remain viable and fertile,
they are more resistant to autoimmune, allergic and inflammatory diseases [47,68,99]. A
genome-wide association study (GWAS) meta-analysis, and other studies, found that the
TYK2 P1104A variant was protective against multiple autoimmune diseases, including
multiple sclerosis (MS), psoriasis, inflammatory bowel disease (IBD), ankylosing spondyli-
tis, rheumatoid arthritis (RA), systematic lupus erythematosus (SLE), and type-I diabetes
(T1D), without increased susceptibility to infection (see Table 1) [31–33,35]. Mouse studies
indicated that the Tyk2 P1104A variant decreased response to IL-12, IL-23 and IFN-I, while
in vitro mutational investigations showed that IFN-α/β, IL-6 and IL-10 signaling remained
intact in TYK2 P1104A cells [39,104]. Interestingly, a recent study describes a TYK2 splice
variant (Rs2304256) that is protective against SLE, T1D and psoriasis [34]. Rs2304256 (V362F
in the FERM domain) contains exon 8, resulting in enhanced TYK2 binding to cytokine
receptors and increased TYK2 gene expression [34]. A meta-analysis of immunochip data
in autoimmune diseases identified the TYK2 SNP rs74956615 as associated with RA, T1D,
and systemic sclerosis (SSc) [30]. Thus, there is a complex balance of TYK2 signaling as
both a mediator of cytokine signaling important in immunity and the involvement of
TYK2 in excessive inflammation and autoimmune dysfunction. In addition, TYK2 plays an
important role in tumor immunosurveillance as well as inflammatory cytokine signaling in
cancer development and metastases, which was recently reviewed [44].
4. Pro-survival Actions of TYK2 and STATs in Cancer
TYK2 has emerged as a pro-survival factor in many types of cancer through stimu-
lation of proliferation and protection from cell death (Figure 3) [105]. In various cancers,
TYK2 overexpression or GOF mutations lead to STAT1 or STAT3 activation and upregula-
tion of anti-apoptotic proteins, including B-cell CLL/lymphoma-2 (BCL-2) and myeloid
cell leukaemia-1 (MCL-1) [20,41]. Recent reports investigated the pro-survival mechanisms
of TYK2 signaling using pharmacologic or genetic inhibition of TYK2 or STAT3 in various
cancer cell lines and mouse tumor models [20,41,106,107]. In human ALCL cells, inhibition
of TYK2 by small molecule inhibitors or genetic depletion decreased proliferation and
induced apoptosis with concomitant reductions in STAT1/STAT3 activation, MCL-1, IL-22
and IL-10 [41]. Correspondingly, loss of Tyk2 in an NPM-ALK lymphoma mouse model
delayed tumor growth and prolonged overall survival [41]. Likewise, TYK2 is highly
expressed in MPNST compared to lower expression in benign precursor plexiform neurofi-
broma tumors [20]. TYK2 deficiency reduces MPNST tumor growth through decreased
proliferation and increased apoptosis mediated via lower phosphorylated STAT3 (p-STAT3)
and BCL-2 with a concomitant increase in caspase 3 cleavage [20]. In esophageal cancer,
TYK2 is also overexpressed, and associated with later stages of disease and shorter patient
survival [106]. The flavonoid cirsiliol blocks TYK2-STAT3 induced cell proliferation and
patient-derived xenograft (PDX) esophageal cancer tumor growth, likely through decreased
C-MYC, BCL-2 and MCL-1 protein levels [106]. Fibroblast growth factor-2 (FGF-2) activates
TYK2 to stimulate proliferation and protect osteosarcoma cells from chemotherapeutic
drugs in vitro [107]. In B-cell lymphoma cells, binding of the CD86 ligand to cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4) results in recruitment and phosphorylation
of TYK2, which activates STAT3 to drive transcription of genes promoting tumor growth
and survival [108]. Similarly, IL-10 activation of TYK2 or GOF mutations in TYK2 promote
survival of T-ALL cells through phosphorylation of STAT1, but not STAT3, and upregula-
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tion of BCL-2 [18]. In head and neck cancer cells, inhibition of STAT3 leads to cell cycle
arrest and apoptosis through pro-apoptotic PARP cleavage and decreases in anti-apoptotic
BCL-xL and survivin [109].
STAT transcription factors have also been widely studied for their role in carcinogene-
sis, as they are frequently mutated or highly activated in cancer [110]. The major oncogenic
actions of TYK2 are mediated through STAT1, STAT3, and STAT5, and drugs targeting
STATs are in development for cancer therapeutics [111,112]. The major cytokines with
upregulated gene expression due to TYK2/STAT signaling include type I IFN, type 2 IFN,
IL-15 and IL-17 [44]. Other STAT target genes are involved in cancer signaling to regulate
cell proliferation (e.g., cyclin D, HSP90), apoptosis (e.g., BCL-2, MCL-1, Bcl-xL), angiogene-
sis (e.g., VEGF-A, FGF), metastasis (e.g., MMP1-3, Vimentin, ICAM-1) and signaling (e.g.,
AKT, PI3K, TNF-R2) [113].
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In some normal and cancer cell types, TYK2 is involved in IFN signaling to induce
apoptosis through pro-apoptotic proteins [119–122]. Type I IFN (i.e., IFN-α, IFN-β) in-
duces apoptosis via TYK2 and STAT1/3 in normal pancreatic β-cells and hematopoietic
cells [119–121]. In addition, the TYK -STAT3 axis mediates β-Amyloid induction of neu-
ronal cell death [123]. In fibrosa coma cells, TYK2 is required for IFN-β-induced mRNA
expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), which
stimulates apoptosis through death receptors [122]. Thus, the proliferative and apoptotic
consequences of TYK2 actions depend on the cell type and context, including the mix of
cytokines, STATs, and downstream signaling pathways.
5. Role of TYK2 in Metastasis
Metastasis is the primary driver of cancer mortality. Thus, it is imperative to under-
stand the molecular mechanisms underpinning metastasis to reduce cancer deaths [124].
Epithelial-to-mesenchymal transition (EMT) is a pre-programmed process by which po-
larized epithelial cancer cells de-differentiate into stem cells that can migrate and invade,
allowing the cells to metastasize to other locations in the body [124,125]. In a series of
recent genomic, proteomic, cell-based nd mouse model studies, TYK2 has emerged as an
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oncogene that promotes migration, invasion and metastasis in multiple types of cancer,
including stomach, MPNST, breast cancer, liver cancer, colon cancer, prostate cancer and
lung cancer [14,20,22,114–116].
Using an RNA-seq bioinformatics approach to compare stomach adenocarcinoma and
normal tissues, TYK2 and JAK3 mRNA expression were positively associated with tumor
grade, stage, and lymph node metastasis status, and patients with high TYK2 expression in
their tumors had shorter overall survival [14]. Therefore, TYK2 and JAK3 may function
as biomarkers in stomach cancer, as they are associated with tumor aggressiveness and
metastasis [14]. A genomic NGS screen showed colorectal cancer metastasis to the liver
contained a TYK2 SNP (rs2304256, V362F), although the mechanism of this mutation
was not investigated [22]. Likewise, a genomic NGS analysis identified activating TYK2
mutations in MPNST [36]. In follow-up studies employing a metastatic mouse xenograft
model with left ventricle tumor injection, shRNA knockdown of Tyk2 decreased MPNST
tumor burden and increased overall survival [20].
The process of invasion is critical in EMT and metastases, and is regulated in part
by tight junction proteins and matrix metalloproteinases (MMP) [126]. In lung cancer, the
tight junction protein claudin-12 stimulates EMT via TYK2 and STAT1 through increased
cell migration and invasion [116]. Additionally, elevated tight junction proteins claudin-
9 and claudin-17 stimulate migration and invasion of hepatocellular carcinoma (HCC)
(liver cancer) cells through activation of the TYK2/STAT3 pathway [115,117]. Similarly,
in prostate cancer cells, inhibition of TYK2 gene expression by shRNA decreases invasion
through decreased urokinase-type plasminogen activator (uPA), which is involved in the
activation of MMPs that degrade extracellular matrix proteins [114,127]. Annexin A1
(AnxA1) functions as a suppressor of EMT and metastasis in breast cancer, and AnxA1
deficiency is associated with poor prognosis and metastasis [118]. Knockdown of AnxA1
induces EMT and metastasis, which is also mediated by TYK2 and STAT3 [118].
As discussed earlier, the role of TYK2 in cancer is complex, and some groups have
reported an inhibitory role of TYK2 in metastases [16,42,128]. Proteomic analysis using
tissue microarrays from a cohort of 70 patients with different breast pathologies revealed
that TYK2 was down-regulated during metastasis to the regional lymph node [16]. In
agreement with this, 4T1 breast cancer cells with TYK2 deficiency demonstrate enhanced
tumor growth and metastasis [42]. Higher levels of TYK2 were also associated with positive
prognosis and immune infiltrate in lung adenocarcinoma [128]. Taken together, all these
data suggest a cell type contextual role of TYK2 in metastasis.
6. Pharmacologic Inhibition of TYK2 for Treatment of Cancer and Metastasis
Selective inhibitors of JAKs (JAK1-3/TYK2) were originally developed as therapeutics
for autoimmune diseases (e.g., rheumatoid arthritis, ankylysing spondylitis and ulcerative
colitis), as well as organ transplantations, due to their ability to suppress the immune
response (Table 2) [129,130]. In 2011, the pan-JAK inhibitor tofacitinib was the first JAK
inhibitor to be FDA-approved to treat rheumatoid arthritis [131,132]. Tofacitinib targets
JAK3 and JAK1, with some effect on JAK2 and a small component on TYK2 [129]. Second
generation JAKinibs, including baricitinib and upadacitinib, were developed to be more
selective and reduce significant side effects [129]. The use of JAK inhibitors (JAKinibs)
was expanded to cancer with the advent of ruxolitinib, a selective JAK1/JAK2 inhibitor
approved to treat the hematological cancers myelofibrosis and polycythemia vera [133].
However, the class of JAK inhibitors, including tofacitinib, baricitinib, and upadacitinib,
have recently undergone further regulatory scrutiny for serious adverse events, with
restrictions now placed on indications and dosage [130].
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In an effort to lessen side effects while improving efficacy, TYK2 inhibitors (TYKinibs)
have become a recent focus in drug discovery [147–149]. Progress in the creation of specific
inhibitors against the different members of the JAK family has been hindered by high
protein homology within the catalytic JH1 domain [150]. The kinase JH1 domain is the
target of most JAKinibs, including the first generation selective TYK2 inhibitors, some of
which show promise as cancer therapeutics [151,152]. A second-generation TYK2 inhibitor,
deucravacitinib (BMS-986165), has recently completed Phase III clinical trials for plaque
psoriasis through blockade of the IL-12, IL-23 and type I IFN pathways [150,153]. Unlike
previous JAKinibs, the highly selective deucravacitinib is directed against the regulatory
JH2 pseudokinase domain of TYK2, and does not inhibit JAK1-3 at clinical therapeutic
doses. Thus, deucravacitinib and other second generation TYKinibs in development are
reported to have better safety profiles than older JAKinibs [141]. Preclinical studies in cell
lines and mice have expanded the use of TYK2 inhibitors to cancer, with the TYKinibs
NDI-031301, SAR-20347 and SAR-20351 inducing regression of T-ALL and solid cancer
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tumors [154,155]. These first and second-generation TYK2 inhibitors present an exciting
opportunity for targeted cancer therapy.
However, as is the case for many targeted therapies, treatment failure can occur
in the setting of intrinsic resistance to JAK or TYK2 inhibitory drugs, or development
of resistance to these drugs over time [156,157]. For example, approximately half of
myeloproliferative neoplasm (MPN) patients become resistant to long-term ruxolitinib
treatment after two to three years, resulting in poor outcomes [158–160]. In vitro studies
attribute ruxolitinib resistance in hematological cancers to either sustained JAK/STAT
activation due to heterodimerization and transactivation of various JAK family members,
to secondary mutations acquired in the JAK2 kinase domain that reduce drug binding,
or to activation of the RAS, ERK and Akt pathways [161–164]. Many MPN patients also
harbor mutations in genes involved in epigenetic regulation, in addition to a mutated
JAK2 V617F [156]. Similarly, despite an initial therapeutic response, ALL cells expressing
the MYB-TYK2 fusion protein eventually become insensitive to the JAK/TYK inhibitor
cerdulatinib after prolonged incubation due to a mutation in the TYK2 kinase domain and
overactive JAK/STAT [157].
Development of combination therapies is one approach to combat resistance. Recent
studies have evaluated several combination therapies in attempts to improve overall
efficacy or overcome resistance to TYKinibs/JAKinibs or other cancer drugs [156,157,164].
In ALL MYB-TYK2 cells with acquired cerdulatinib resistance, histone deacetylase inhibitor
(HDACi) therapy proved efficacious in blocking proliferation [157]. Likewise, heat shock
protein 90 (HSP90) inhibitors combined with JAK inhibitors (e.g., ruxolitinib, TG101209)
overcome JAKinib resistance in leukemia and MPN cells [165,166]. Indeed, response to
combination therapy consisting of ruxolitinib with the HSP90 inhibitor, HDACi, and/or
chemotherapy was superior to monotherapy in both preclinical murine studies, as well
as in early studies in patients with leukemia [156]. Ruxolitinib resistance can also be
bypassed with subsequent treatment with another JAK2 inhibitor, including fedratinib,
pacritinib and momelotinib [167]. In addition, TYK2 and JAK inhibitors are starting
to be evaluated in combination with chemotherapy drugs or other pathway inhibitors.
For example, the selective TYK2 inhibitor SAR-20351 acts synergistically in combination
with the chemotherapeutic 5-fluorouracil (5-FU) or anti-CTLA-4 therapy in colon cancer
mouse models, or with everolimus, an mTOR kinase inhibitor, in a renal cell cancer mouse
model [155]. Similarly, while colorectal cancer cells can evade inhibition of JAK1/2 through
aberrant activation of the RAS-MEK-ERK pathway, combination therapy with the JAK1/2
inhibitor momelotinib sensitizes these cells to trametinib, a MEK inhibitor [168].
7. Conclusions and Perspectives
Personalized, or precision, medicine has increasingly become a valuable tool in clinical
diagnostics to evaluate potential therapeutic options for individual cancer patients [169].
Based on genetic mutations, gene expression or protein level changes in patient tumors for
known oncogenes or tumor suppressors, personalized medicine can aid in prognostication,
as well as predict responses to anti-cancer agents [170]. Given the identification of TYK2 as
a potential biomarker for numerous types of cancer, evaluation of patient tumors for TYK2
mutations or expression levels may help determine patient prognosis. In addition, with the
development of multiple pharmacologic inhibitors of TYK2 and JAKs, those tumors that are
TYK2-positive may be viable candidates for TYKinib/JAKinib targeted therapies. Future
pre-clinical studies should be geared at evaluating therapeutic interventions with TYK2
inhibitors as single agents, or in combination therapy to pave the way for biomarker-driven
clinical trials.
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